Cocaine Hydrochloride

Jan. 28, 2025 -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the strengthening of its foothold throughout Europe and the Middle East through its partnership with IVY Diagnostics Srl (“IVY Diagnostics”). As a key distributor, IVY Diagnostics is playing an integral role in expanding the adoption of INBS' Intelligent Fingerprinting Drug Testing Solution across Europe and the Middle East, with a particular focus on drug rehabilitation and law enforcement applications. According to Grand View Research, the European and Middle Eastern drug screening markets are projected to grow significantly by 2030, with Europe expected to reach $3.6 billion1 and the Middle East and Africa $432.7 million2. This growing demand emphasises the strategic importance of INBS' partnership with IVY Diagnostics. IVY Diagnostics, a well-known consulting and distribution company within the diagnostics, life sciences and pharmaceutical sectors, has collaborated with another Italian distributor to secure a tender to provide INBS' drug screening technology for drug rehabilitation programs across Italy. The solution offers a non-invasive, rapid, and hygienic method for drug screening, which has been well received by rehabilitation centres aiming to enhance their testing protocols. In addition to its success in rehabilitation services, INBS' drug screening system is currently undergoing a trial with the local police force in Turin. The trial aims to explore the effectiveness of fingerprint-based drug testing in roadside screening initiatives, offering a more efficient, less invasive alternative to the traditional methods currently used. As the demand for drug screening solutions rises across Europe and the Middle East, INBS’ collaboration with IVY Diagnostics positions the Company to effectively capture new opportunities. IVY Diagnostics serves as INBS' primary contact in Europe, leveraging its extensive network of distributors and expertise in identifying and vetting new partners across key regions, including Romania, Hungary, Slovakia, Austria, and Scandinavia. The collaboration extends to the Middle East, targeting markets such as the UAE, Saudi Arabia, and Qatar. "Our strategic partnership with IVY Diagnostics plays a key role in introducing our fingerprint sweat-based drug screening technology to new markets and industries," said Doug Heath, Vice President of Global Sales at Intelligent Bio Solutions. "Their deep understanding of the regulatory landscape, coupled with their extensive connections across Europe and the Middle East, positions them as an invaluable partner in our mission to provide safer and more efficient drug testing solutions worldwide." IVY Diagnostics is enthusiastic about raising awareness around the benefits of fingerprint-based drug testing technology, working closely with stakeholders to highlight its applications in sectors requiring stringent drug testing protocols. The efforts of IVY Diagnostics align with INBS' vision to transform drug screening through innovative, non-invasive, and accessible solutions. IVY Diagnostics Srl is a dynamic company operating in the diagnostics and life sciences sectors, with a focus on Point of Care Testing (POCT) and rapid testing solutions. Since its foundation in 2013, IVY Diagnostics has grown steadily, expanding its portfolio to include proprietary and distributed diagnostic products, as well as consulting services aimed at supporting clients worldwide. The company is recognized for its commitment to innovation and quality, having launched advanced solutions such as the easyTOX™ drug detection system and established a strong presence in international markets. IVY Diagnostics combines flexibility and customer focus to deliver impactful solutions for healthcare professionals and organizations globally. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. ____________________ Hyperlinks and website references in this release are provided for convenience only and do not incorporate the referenced content into this release. 1 Grand View Research. Europe Drug Screening Market Size & Outlook, 2023-2030. Available at: https://www.grandviewresearch.com/horizon/outlook/drug-screening-market/europe 2 Grand View Research. Middle East and Africa Drug Screening Market Size & Outlook. Available at: https://www.grandviewresearch.com/horizon/outlook/drug-screening-market/mea The content above comes from the network. if any infringement, please contact us to modify.

人工智能不再是科幻小说中的遥远设想，而是已经深刻融入社会的方方面面，成为推动经济增长、社会进步和科技革新的核心驱动力。从智能手机中的语音助手，到医疗领域的智能诊断系统；从金融行业的风险预测，到工业生产中的自动化流程，人工智能正以前所未有的速度重塑我们的生活方式、工作模式以及社会运行机制。 在人工智能发展的璀璨星空中，OpenAI 和 DeepSeek 是两颗格外耀眼的新星。OpenAI 作为人工智能领域的开拓者，凭借突破性的研究成果和强大的模型（如 ChatGPT、GPT-4o 和 o1 大模型等），在全球范围内掀起了人工智能的热潮。其在自然语言处理和对话系统等领域引领潮流，成为行业标杆，并激励着无数开发者和研究者竞相追赶。 与此同时，DeepSeek 作为中国人工智能领域的崛起力量，自问世以来就备受关注。其推出的 DeepSeek-V3 和 DeepSeek-R1 模型以卓越的性能、低廉的训练成本和创新的开源理念迅速崭露头角，在国际 AI 社区中引发了广泛讨论。2025 年 1 月 20 日，DeepSeek 发布了推理模型 DeepSeek-R1 正式版，展示了与 OpenAI o1 正式版媲美的强大实力。在理科领域，该模型能够快速解决复杂的高考压轴题，甚至生成解释量子力学概念的代码动画；在文科领域，其推理能力显著提升，能够准确解答脑筋急转弯问题，并深入分析历史事件。 此外，DeepSeek-R1 在开源策略上采取了大胆举措，其 API 服务定价极具吸引力：每百万输入 tokens 1 元（缓存命中）/4 元（缓存未命中），每百万输出 tokens 16 元。这一低成本方案为开发者和研究者提供了强有力的支持，大幅降低了人工智能创新和应用的门槛，从而进一步推动了技术进步与普及。 OpenAI 和 DeepSeek 的快速发展不仅标志着人工智能技术的重大突破，也预示着一个全新时代的到来。它们的竞争与合作将深刻影响未来的科技格局、经济发展、社会结构及人类生活方式。对 OpenAI 和 DeepSeek 的大模型进行深入对比分析，并探讨其对未来世界的深远影响，具有重要的现实意义和战略价值。 一、疾病诊断中的应用 选择NEJM上发表的最新的病例，相信两个模型都没有学习过。 病例为一名患有劳力性呼吸困难和胸痛的 54 岁男性： https://www.nejm.org/doi/full/10.1056/NEJMcpc2300900 病例翻译的大体内容如下：  一名 54 岁的男性运动员因进行性劳力性呼吸困难和胸痛，在本院心血管体能表现计划诊所接受了评估。 患者一直处于正常健康状态，包括定期进行剧烈运动，直到此次就诊前 17 个月，才出现间歇性非放射性胸闷和运动时呼吸困难。在高强度有氧运动期间，他感到无法“充分呼吸”。胸部不适的唯一其他病史是左侧胸部钝痛持续 2 天，发生在本次就诊前 5 年乘坐飞机旅行后。当时的评估显示，血液中的肌钙蛋白水平正常，心电图显示窦性心动过缓。 本次就诊前五年，患者根据加速胸痛诊断方案接受了冠状动脉计算机断层扫描血管造影 (CTA)。患者的冠状动脉疾病报告和数据系统 (CAD-RADS) 评分为 0（范围为 0 至 5，评分越高表示动脉粥样硬化斑块越多或狭窄越严重），冠状动脉钙化评分为 0，表示无钙化。患者无管腔狭窄或非钙化斑块。心腔形态正常（即舒张末期正常大小和正常壁厚），影像学表现与左心室静息收缩功能正常相符。 本次就诊前 16 个月，由其初级保健医生进行了评估。检查时发现患者有 2/6 级收缩中期杂音，此前未发现。心电图检查显示，与本次就诊前 5 年的心电图相比，患者心律正常、新的右向电轴、R 波进展减慢和新的下侧 T 波倒置。胸部 X 光检查结果正常，实验室检查结果也正常，包括全血细胞计数、肾功能指标以及血液电解质、天冬氨酸氨基转移酶、丙氨酸氨基转移酶、白蛋白、总蛋白、铁、D-二聚体和促甲状腺激素水平。患者开始接受阿司匹林治疗，并计划进行其他心脏检查。 10 天后，患者接受了负荷超声心动图检查。患者静息时的心电图显示 T 波倒置，超声心动图显示左心室运动亢进，二尖瓣轻度反流。骑自行车运动 11 分钟后，患者出现轻度胸闷和呼吸困难，下侧导联出现水平和下坡 ST 段压低（2 毫米），但未检测到可诱发的左心室壁运动异常。 六周后，即本次就诊前 14 个月，患者在本院心脏病门诊接受评估。患者报告剧烈运动时持续出现间歇性胸闷和劳力性呼吸困难。体格检查报告正常。心电图显示 T 波倒置比之前的影像学检查更明显，aVL 导联出现新的 Q 波。经胸超声心动图显示左心室动力亢进，壁对称增厚（17 毫米），收缩期腔内左心室闭塞，无流出道或中腔梯度，双心房和下腔静脉扩张，右心室壁增厚，二尖瓣增厚。进行了额外的影像学检查。 心脏磁共振成像 (MRI) 证实了左心室壁向心性增厚，增厚程度可达 18 毫米，左心室壁厚度从底部到心尖没有逐渐变薄。未发现心肌水肿的证据；然而，在中壁心尖室间隔处存在局灶性晚期钆增强 (定义为高于参考信号强度 6 个标准差)，影响了 3% 的左心室心肌。二尖瓣前叶似乎轻度延长。这些发现提示但不能诊断为肥厚型心肌病。 动态心电图显示偶尔出现异位搏动，一次 3 次心室搏动和短暂的室上搏动。对与肥厚性心肌病相关的 56 种基因（包括编码肌球蛋白、肌联蛋白、层蛋白、甲状腺素运载蛋白和 AMP 活化蛋白激酶 γ2 亚基的基因）进行基因检测的结果为阴性。该患者的成年子女接受了超声心动图检查，结果显示心室壁增厚为阴性。 在接下来的一年中，患者的症状持续存在。重复负荷超声心动图检查显示峰值负荷时二尖瓣轻度反流，左心室流出道梯度峰值为 12 毫米汞柱；运动时血压适当升高。他被转诊至本院心血管功能计划门诊进行心肺运动测试、运动指导和运动处方。 在心血管功能计划门诊，患者报告终身从事体育活动，包括在大学期间参加多项运动，大学毕业后保持骑自行车、曲棍球和划船等剧烈运动；他在四十岁时开始参加铁人三项比赛。他描述了在本次就诊前 17 个月内运动耐受力的隐匿但进行性下降，同时运动后恢复难度增加。他报告说，饭后遛狗时出现上腹部不适和腹胀，并有 2 周的声音嘶哑病史。此外，他报告没有晕厥、头晕、心悸、出汗或潮红。他没有水肿、端坐呼吸、阵发性夜间呼吸困难、体重变化、瘀伤或出血或神经系统症状。他没有接种COVID-19疫苗。 患者的病史包括关节炎、修复双侧肩袖撕裂的手术、双膝半月板切除术和结肠息肉。药物包括阿司匹林；他没有已知的药物不良反应。患者是一名高管，与家人住在新英格兰郊区。他在社交场合喝酒，很久以前曾使用过鼻腔内可卡因；他从未吸过烟。他的家族史包括父亲患有早发性冠状动脉疾病和心力衰竭；母亲患有高血压、心房颤动和心力衰竭；多名亲属患有血脂异常。 检查时，心率为每分钟 81 次，血压为 116/70 毫米汞柱。颈静脉压为 13 厘米水柱，并有库斯马尔征。躯干皮肤上可见小血管瘤（<4 毫米）。其余检查均正常。 与就诊前 5 年的心电图相比，患者静息时的心电图显示窦性心律、电轴右移、T 波倒置、QRS 振幅降低。心肺运动试验显示最大耗氧量降低至 19.7 ml/kg 体重/分钟（与年龄和性别匹配的非运动对照组相比，为预测值的 59%），通气阈值为峰值耗氧量的 83%，氧脉搏增强受损（这是每搏输出量增强的替代指标）。由于患者的肺量和氧合正常，这些发现表明由于心血管功能受限导致严重的运动障碍。 血液白蛋白、球蛋白、总蛋白、促甲状腺激素水平正常。 要求两个人工智能分别进行诊断和鉴别诊断。 《新英格医学杂志》上专家给出的判断： 鉴别诊断：肥厚性心肌病、限制性心肌病 临床诊断：肥厚性心肌病类似，最有可能是心脏淀粉样变性。 Clyde W. Yancy 医生的诊断：由于与淀粉样变性一致的浸润过程导致的限制性心肌病。 你认为哪个人工智能胜出？ 二、专业翻译。看翻译的易懂性如何？ 这是一份摘要，见： Background Out-of-hospital cardiac arrest is a leading cause of death worldwide. Establishing vascular access is critical for administering guideline-recommended drugs during cardiopulmonary resuscitation. Both the intraosseous route and the intravenous route are used routinely, but their comparative effectiveness remains unclear. Methods We conducted a randomized clinical trial to compare the effectiveness of initial attempts at intraosseous or intravenous vascular access in adults who had nontraumatic out-of-hospital cardiac arrest. The primary outcome was a sustained return of spontaneous circulation. Key secondary outcomes were survival at 30 days and survival at 30 days with a favorable neurologic outcome, defined by a score of 0 to 3 on the modified Rankin scale (scores range from 0 to 6, with higher scores indicating greater disability). Results Among 1506 patients who underwent randomization, 1479 were included in the primary analysis (731 in the intraosseous-access group and 748 in the intravenous-access group). The successful establishment of vascular access within two attempts occurred in 669 patients (92%) assigned to the intraosseous-access group and in 595 patients (80%) assigned to the intravenous-access group. Sustained return of spontaneous circulation occurred in 221 patients (30%) in the intraosseous-access group and in 214 patients (29%) in the intravenous-access group (risk ratio, 1.06; 95% confidence interval [CI], 0.90 to 1.24; P=0.49). At 30 days, 85 patients (12%) in the intraosseous-access group and 75 patients (10%) in the intravenous-access group were alive (risk ratio, 1.16; 95% CI, 0.87 to 1.56); a favorable neurologic outcome at 30 days occurred in 67 patients (9%) and 59 patients (8%), respectively (risk ratio, 1.16; 95% CI, 0.83 to 1.62). Prespecified adverse events were uncommon. Conclusions There was no significant difference in sustained return of spontaneous circulation between initial intraosseous and intravenous vascular access in adults who had out-of-hospital cardiac arrest.  两个人工智能翻译对比： 大家比较一下，翻译的质量如何？整体而言，chatGPT略优一点。 三、治疗方案 胸骨正中切开术、无名静脉置换上腔静脉及碘植入术治疗复发性胸腺癌的病例，见：https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70089 病例信息如下： A 51-year-old male with no previous medical history, no smoking history, and no history of chronic lung disease. The patient presented to The General Hospital of the People's Liberation Army on November 30, 2021, with the chief complaint of “Eyelid edema in the morning for 1 month” Chest three-dimensional computed tomography (CT) revealed a mass shadow in the anterior superior mediastinum. Further positron emission tomography/computed tomography (PET/CT) examination at Zunyi Medical University Affiliated Hospital on November 23, 2021, indicated an anterior mediastinal mass with increased metabolism, suggesting malignant lesions, with enlargement of mediastinal lymph nodes 3a and 6, indicating possible metastasis. After excluding relevant surgical contraindications, the patient underwent “thoracoscopic resection of anterior mediastinal tumor and wedge resection of the left upper lobe of the lung” on December 2, 2021. Postoperative pathology revealed (anterior mediastinum) NEC, G3 with necrosis, tumor invasion into the lung parenchyma, and > 20 mitotic figures/10 high-power fields. Lymph nodes in the hilum showed no metastatic carcinoma (0/1). Immunohistochemistry results were positive for CK, Syn, CgA, CD56, and Ki-67 (40%) and negative for S-100. Pathological diagnosis: Masaoka stage IVa. Postoperative follow-up chest CT showed partial loss of the left upper lobe of the lung, with a small amount of pneumonia and localized lung consolidation. Postoperative diagnosis: T3NOMO stage IIIA, based on the 8th edition of the American Joint Committee on Cancer (AJCC) staging system.  让两个人工智能给出治疗方案。 小结 OpenAI 和 DeepSeek 的人工智能技术在多项测试中表现出色，整体实力旗鼓相当。通过这些测试，公众对人工智能有了初步的认识和了解。展望未来，人工智能毫无疑问将成为推动世界变革的核心力量，对社会、经济、文化等领域产生深远而持久的影响。 然而，在人工智能技术快速发展的同时，我们也需要理性看待随之而来的伦理与安全挑战。在伦理方面，人工智能可能会改变就业结构，大量重复性和规则化的工作可能被取代，这可能引发失业和社会不平等问题。为此，我们需要加强劳动者的技能培训与再教育，帮助他们适应人工智能时代的就业需求。此外，人工智能的应用还带来了数据隐私与安全的潜在风险。我们必须强化数据保护和安全管理，制定完善的法律法规，确保个人隐私和数据的安全。 尽管挑战重重，人工智能的发展潜力依然巨大。它为人类带来了前所未有的机遇与可能性。我们需要充分发挥人工智能的优势，同时积极应对潜在的问题，努力实现人工智能与人类社会的协调发展，推动构建一个更加和谐的未来。 OpenAI 和 DeepSeek 的竞争与进步，正是人工智能浪潮的缩影。随着技术的不断突破与创新，我们有理由相信，人工智能将在更多领域取得重大成就，为人类创造更加高效、便捷和美好的生活。让我们携手努力，共同迎接人工智能时代的到来，构建一个智能化、高效化、繁荣共赢的未来世界。